NASDAQ:PRLD

Prelude Therapeutics Competitors

$32.70
-2.56 (-7.26 %)
(As of 04/12/2021 04:30 PM ET)
Add
Compare
Today's Range
$32.51
Now: $32.70
$36.05
50-Day Range
$37.39
MA: $54.96
$76.96
52-Week Range
$23.69
Now: $32.70
$95.38
Volume369,359 shs
Average Volume221,544 shs
Market Capitalization$1.52 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Prelude Therapeutics (NASDAQ:PRLD) Vs. ARWR, TGTX, IONS, SRPT, ALLK, and BPMC

Should you be buying PRLD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Prelude Therapeutics, including Arrowhead Pharmaceuticals (ARWR), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Allakos (ALLK), and Blueprint Medicines (BPMC).

Prelude Therapeutics (NASDAQ:PRLD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Insider and Institutional Ownership

76.2% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Prelude Therapeutics and Arrowhead Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals$87.99 million74.05$-84,550,000.00($0.84)-74.74

Prelude Therapeutics has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Prelude Therapeutics and Arrowhead Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03102.25
Arrowhead Pharmaceuticals021002.83

Prelude Therapeutics presently has a consensus price target of $54.25, suggesting a potential upside of 66.56%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, suggesting a potential upside of 35.82%. Given Prelude Therapeutics' higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Profitability

This table compares Prelude Therapeutics and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Summary

Prelude Therapeutics beats Arrowhead Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Insider and Institutional Ownership

76.2% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Prelude Therapeutics and TG Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
TG Therapeutics$150,000.0041,144.84$-172,870,000.00($1.83)-23.99

Prelude Therapeutics has higher earnings, but lower revenue than TG Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Prelude Therapeutics and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03102.25
TG Therapeutics00503.00

Prelude Therapeutics presently has a consensus price target of $54.25, suggesting a potential upside of 66.56%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 45.75%. Given Prelude Therapeutics' higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than TG Therapeutics.

Profitability

This table compares Prelude Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
TG Therapeutics-151,798.69%-223.96%-108.08%

Summary

Prelude Therapeutics beats TG Therapeutics on 5 of the 9 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Prelude Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03102.25
Ionis Pharmaceuticals27602.27

Prelude Therapeutics presently has a consensus price target of $54.25, suggesting a potential upside of 66.56%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 41.73%. Given Prelude Therapeutics' higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Ionis Pharmaceuticals.

Insider and Institutional Ownership

76.2% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Prelude Therapeutics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Ionis Pharmaceuticals7.82%6.57%3.39%

Earnings & Valuation

This table compares Prelude Therapeutics and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Ionis Pharmaceuticals$1.12 billion5.13$303.26 million$2.0819.65

Ionis Pharmaceuticals has higher revenue and earnings than Prelude Therapeutics.

Summary

Ionis Pharmaceuticals beats Prelude Therapeutics on 8 of the 9 factors compared between the two stocks.

Sarepta Therapeutics (NASDAQ:SRPT) and Prelude Therapeutics (NASDAQ:PRLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sarepta Therapeutics and Prelude Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191202.50
Prelude Therapeutics03102.25

Sarepta Therapeutics presently has a consensus price target of $150.4762, suggesting a potential upside of 116.89%. Prelude Therapeutics has a consensus price target of $54.25, suggesting a potential upside of 66.56%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sarepta Therapeutics is more favorable than Prelude Therapeutics.

Insider and Institutional Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sarepta Therapeutics and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Prelude TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Sarepta Therapeutics and Prelude Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million14.47$-715,080,000.00($9.71)-7.15
Prelude TherapeuticsN/AN/AN/AN/AN/A

Prelude Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics.

Summary

Sarepta Therapeutics beats Prelude Therapeutics on 6 of the 9 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Prelude Therapeutics (NASDAQ:PRLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Allakos and Prelude Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Prelude Therapeutics03102.25

Allakos presently has a consensus price target of $181.50, suggesting a potential upside of 73.95%. Prelude Therapeutics has a consensus price target of $54.25, suggesting a potential upside of 66.56%. Given Allakos' stronger consensus rating and higher possible upside, equities research analysts plainly believe Allakos is more favorable than Prelude Therapeutics.

Insider and Institutional Ownership

65.4% of Allakos shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. 44.8% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Allakos and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Prelude TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Allakos and Prelude Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-55.24
Prelude TherapeuticsN/AN/AN/AN/AN/A

Summary

Allakos beats Prelude Therapeutics on 4 of the 7 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Prelude Therapeutics (NASDAQ:PRLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Blueprint Medicines and Prelude Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Prelude Therapeutics03102.25

Blueprint Medicines presently has a consensus price target of $111.00, suggesting a potential upside of 19.87%. Prelude Therapeutics has a consensus price target of $54.25, suggesting a potential upside of 66.56%. Given Prelude Therapeutics' higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Blueprint Medicines.

Insider and Institutional Ownership

76.2% of Prelude Therapeutics shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Blueprint Medicines and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Prelude TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Blueprint Medicines and Prelude Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million80.70$-347,690,000.00($7.27)-12.74
Prelude TherapeuticsN/AN/AN/AN/AN/A

Prelude Therapeutics has lower revenue, but higher earnings than Blueprint Medicines.

Summary

Blueprint Medicines beats Prelude Therapeutics on 8 of the 10 factors compared between the two stocks.


Prelude Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.78-1.0%$6.45 billion$87.99 million-74.74News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$43.90-2.0%$6.30 billion$150,000.00-20.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.87-3.6%$5.97 billion$1.12 billion85.15
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.38-1.7%$5.60 billion$380.83 million-8.87
Allakos logo
ALLK
Allakos
1.7$104.41-0.6%$5.58 billionN/A-38.11
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.61-1.7%$5.46 billion$66.51 million17.09
Perrigo logo
PRGO
Perrigo
2.5$40.52-0.0%$5.41 billion$4.84 billion-675.22
Schrödinger logo
SDGR
Schrödinger
1.5$73.88-0.0%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.39-0.5%$5.10 billion$1.00 billion-11.73Analyst Report
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31-2.2%$4.68 billionN/A0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.47 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.31 billionN/A-5.77Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-0.2%$4.26 billion$204.89 million-36.63Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.12 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76-2.4%$4.00 billion$806.43 million-9.17Unusual Options Activity
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94-5.4%$3.87 billionN/A-21.35News Coverage
LEGN
Legend Biotech
1.2$27.81-2.3%$3.76 billion$64.39 million0.00Gap Up
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.72 billion$4.31 million-1.66Gap Up
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.44 billion$36.13 million-69.12
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.40 billion$114.62 million-7.53Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.35 billion$306.98 million-6.74
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.27 billion$136.47 million-11.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.26 billion$339.08 million-11.88
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.20 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.16 billionN/A-56.03Gap Up
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$3.10 billion$42.98 million-23.61
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$3.03 billion$1.17 billion-40.83Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.99 billion$421.03 million23.93Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.94 billion$80.43 million105.58
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.92 billion$260.98 million-383.00Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.80 billion$901.90 million-22.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.79 billion$644.77 million-10.36
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.66 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.56 billion$60,000.00-9.85News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.56 billionN/A0.00
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.55 billion$120.28 million-146.36
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.53 billion$2.11 million-8.65
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.52 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.43 billionN/A-22.51
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.43 billion$182.24 million-8.08
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.38 billion$33.94 million-89.03Insider Selling
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.35 billion$156.70 million-28.28News Coverage
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.33 billion$429.76 million-116.78
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.22 billion$15 million-15.96
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.18 billion$963.01 million13.76
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$2.10 billionN/A-26.43
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$2.01 billion$410,000.00-6.07
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.